TPST Tempest Therapeutics: Rasio rega marang prakiraan pendapatan
The projected P/S dynamics reflect market revenue expectations, where represents the current level of the metric. Tempest Therapeutics (TPST) is preparing large-scale Phase III trials for liver cancer therapy, attracting biopharmaceutical partners. Market capitalization growth is driven by the success of the drug TPST-1495 and interest from industry behemoths. Development is led by an elite staff of chemists and oncologists motivated by stock option programs.
Rincian analitis perusahaan Tempest Therapeutics
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- indikator nilai buku ekuitas:
- data tingkat utang lan likuiditas finansial:
Utang marang Ekuitas Tempest Therapeutics|TPST - Rasio tanggungan utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Tempest Therapeutics|TPST - Tanggungan utang kumulatif perusahaan|Utang marang nilai buku Tempest Therapeutics Corp|TPST - Silihan lan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Tempest Therapeutics|Rasio cepet tempesttx.com
- data bathi bisnis lan rasio investasi:
TPST - Bathi pungkasan|Proyeksi bathi mangsa ngarep Tempest Therapeutics|TPST - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Tempest Tx|TPST - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Tempest Therapeutics Corp|TPST - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Tempest Therapeutics|TPST - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan tempesttx.com|TPST - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Tempest Therapeutics
- informasi babagan volume dodolan lan pendapatan:
Analisis umum perusahaan:Tempest Therapeutics, Inc. (TPST)
For Tempest Therapeutics (TPST), whose capitalization relies on future royalties from liver cancer therapy, the forward P/S history reflects market expectations regarding revenue scalability. The current value of shows a premium to expected sales, allowing investors to assess the fairness of the business valuation relative to the projected market share capture without waiting for quarterly reports.
Pesaing wigati
Multiplikator Forward P/S ONC (BeiGene)|Halozyme Therapeutics, Inc. (HALO) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RVMD - Rasio rega marang prakiraan pendapatan|Ascentage Pharma Corp (AAPG) - Multiplikator forward rega marang pendapatan|CG Oncology, Inc. (CGON) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan URGN (urogen.com)|BCAX (Bicara Therapeutics) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Personalis Inc PSNL|Rasio rega marang prakiraan pendapatan Erasca Corp (ERAS)|Rasio kapitalisasi marang dodolan sing dikarepake Delcath Corp|Y-mAbs Therapeutics - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake AURA (aurabiosciences.com)|CADL: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ARAY (Accuray Inc)|SLS (sellaslifesciences.com) - Multiplikator forward rega marang pendapatan|ACTU: Rasio rega marang pendapatan sing dikarepake|CTOR (Citius Oncology, Inc.) - Multiplikator Forward P/S|HURA: Rega forward marang dodolan|Multiplikator Forward P/S TARA|FATE - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Aadi Bioscience WHWK|Rega forward marang dodolan TCRX|Champions Oncology Corp - Multiplikator Forward P/S|XBIT - Multiplikator Forward P/S|cel-sci.com (CVM) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan OSTX (OS Therapies Inc.)|RADX (Radiopharm Theranostics Limited) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Artiva ARTV|Multiplikator forward rega marang pendapatan ANL (Adlai Nortye Ltd.)|Multiplikator Forward P/S verupharma.com (VERU)|Xilio Therapeutics - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake RENB (Renovaro Biosciences)|Mural Bio - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Kairos Pharma Ltd KAPA|OKUR: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan CytoMed Therapeutics Limited|Rasio rega marang prakiraan pendapatan Curis Inc.|Apollomics Corp (APLM) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan THAR (Tharimmune Corp)|Rasio rega marang pendapatan sing dikarepake ADVB|Rasio rega marang prakiraan pendapatan Genprex, Inc. GNPX|CLDI (Calidi Biotherapeutics Inc.) - Rega mangsa ngarep marang pendapatan|SBFM - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Xenetic Biosciences XBIO|SLRX (Salarius) - Multiplikator forward rega marang pendapatan|PPBT: Rasio rega marang pendapatan sing dikarepake|AONC (American Oncology Network Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan beigene.com (BGNE)|Multiplikator Forward P/S CKPT|Multiplikator Forward P/S elevationoncology.com (ELEV)|Rasio rega marang prakiraan pendapatan iCAD ICAD|IKNA: Kapitalisasi marang prakiraan pendapatan|Notable Labs, Ltd. - Multiplikator Forward P/S|Viracta Therapeutics (VIRX) - Multiplikator forward rega marang pendapatan|MOR: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep NAYA Biosciences Inc (NAYA)|Rasio rega marang prakiraan pendapatan Ascentage Pharma Group Ltd
